Guess which ASX 300 share has rocketed 27% in 2 days since reporting

A barrage of news has sent one stock soaring this week.

| More on:
Health workers shake hands and congratulate each other on good news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Mayne Pharma share price is trading at $4 right now – 27% higher than it was prior to entering a trading halt ahead of Monday's open
  • The company announced a US$90 million divestment and the cancellation of its capital return over the course of Monday and Tuesday
  • It also released its earnings for the first half yesterday morning, with management dubbing the performance of some of its businesses "disappointing"

The share price of S&P/ASX 300 Index (ASX: XKO) stock Mayne Pharma Group Ltd (ASX: MYX) has soared since the company dropped its half-year earnings on Tuesday morning.

Right now, the pharmaceutical manufacturer's stock is trading at $4 – 27% higher than it was before it broke a trading halt with news of its results, a divestment, and its capital return.

Let's take a closer look at what's been going right for the ASX 300 share this week.

ASX 300 share Mayne Pharma rockets 27% in 2 sessions

Here are the key takeaways from Mayne Pharma's first-half earnings:

The company's earnings were dinted by lower revenues, driven by higher inventory levels, discontinued products, and foreign exchange losses.

The company's branded products division saw revenue more than triple to $13.4 million last half amid strong growth in NEXSTELIS sales. Its portfolio products division saw revenue fall 49% to $60.1 million. Finally, its international segment's revenue was flat at $27.6 million.

What else did the company announce this week?

The Mayne Pharma share price was put into a trading halt on Monday morning, returning to trade on Tuesday, as the ASX 300 company prepared to release news of a material divestment and its capital management.

Later that day, it announced the sale of its US retail generics portfolio business for up to US$90 million cash and up to US$15 million of contingent milestone payments.

The move supports the company's aim to transform into a speciality pharmaceutical company with leading positions in women's health and dermatology.

It also announced the cancellation of its $113 million capital return on Tuesday. It said the return was no longer in the company's best interests.

What did management say?

Mayne Pharma CEO Shawn Patrick O'Brien commented on the news seemingly driving the ASX 300 share sky-high in recent sessions, saying:

We have taken decisive action this half to address the issues that have created the disappointing results in both our PPD and International businesses.

We are creating a leaner company with strong commercial and sales execution capabilities and [with the sale of the US retail generics business] we move a step closer to achieving our goal of generating operating cash and returning the business to profitability.

The board is supportive of our strategy and ambition, and the cancellation of the capital return is a prudent step to retain balance sheet flexibility whilst we drive improved operating performance, and the board considers the appropriate capital structure to support profitable growth and a restoration of shareholder value.

What's next?

The company heralded an encouraging start to the second half. It flagged improvement in its dermatology segment and positive impacts from the scaling up of its US women's health business.

The latter is on track to exit financial year 2023 with a positive run rate contribution. Meanwhile, the newly acquired TherapeuticsMD portfolio is expected to deliver positive earnings in the second half.

At the same time, launches of various products are expected to drive growth across the company.

Maybe Pharma share price underperforms the ASX 300

Despite this week's surge, the Mayne Pharma share price is still in the longer-term red.

It has fallen 5% so far this year and 13% over the last 12 months.

For comparison, the ASX 300 has gained 4% year to date and 2% over the last 12 months.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

Doctor doing a telemedicine using laptop at a medical clinic
Earnings Results

Polynovo share price surges after 57% revenue gain in FY24

Global sales continue to grow for Polynovo.

Read more »

two men in hard hats and high visibility jackets look together at a laptop screen that one of the men in holding at a mine site.
Earnings Results

Paladin Energy share price in focus on quarterly production data

The uranium producer had a reasonably constructive quarter.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Earnings Results

ASX 200 stock jumps 10% on strong FY24 results

How did this KFC restaurant operator perform in FY 2024?

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Consumer Staples & Discretionary Shares

Guess which ASX 200 stock just slashed its final dividend by 23%

This retailer had a tough time during the 12 months. Here's how it performed.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Earnings Results

Catapult shines: 20% sales growth propels ASX tech stock to new 52-week high

A strong annual result from this tech player has caught investor attention.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Earnings Results

Xero share price leaps 8% on staggering earnings upheaval

A major turnaround in profitability is sending investors into a frenzy over Xero shares today.

Read more »

a construction worker sits pensively at his desk with his arm propping up his chin as he looks at his laptop computer while wearing a hard hat and visibility vest in a bunker style construction shed.
Materials Shares

Which ASX 200 stock just plunged 12% despite record full-year earnings?

It looks like an impressive report card but UBS doesn't like the FY25 guidance.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Earnings Results

ASX 200 tech stock lifts off on another record-setting half-year profit

Investors are bidding up the ASX 200 tech company following its half-year results.

Read more »